Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).

Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH.

Ann Oncol. 2014 Sep;25(9):1807-12. doi: 10.1093/annonc/mdu231. Epub 2014 Jun 19.

PMID:
24948692
2.

Forodesine in the treatment of cutaneous T-cell lymphoma.

Lewis DJ, Duvic M.

Expert Opin Investig Drugs. 2017 Jun;26(6):771-775. doi: 10.1080/13543784.2017.1324569. Epub 2017 May 5. Review.

PMID:
28447489
3.

Mycosis fungoides: pathophysiology and emerging therapies.

Duvic M, Foss FM.

Semin Oncol. 2007 Dec;34(6 Suppl 5):S21-8. Review.

PMID:
18086343
4.

Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies.

Ogura M, Tsukasaki K, Nagai H, Uchida T, Oyama T, Suzuki T, Taguchi J, Maruyama D, Hotta T, Tobinai K.

Cancer Sci. 2012 Jul;103(7):1290-5. doi: 10.1111/j.1349-7006.2012.02287.x. Epub 2012 Apr 30.

5.

Bexarotene therapy for mycosis fungoides and Sézary syndrome.

Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ.

Br J Dermatol. 2009 Jun;160(6):1299-307. doi: 10.1111/j.1365-2133.2009.09037.x. Epub 2009 Feb 16.

PMID:
19222457
6.

Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.

Korycka A, Błoński JZ, Robak T.

Mini Rev Med Chem. 2007 Sep;7(9):976-83. Review.

PMID:
17897085
7.
8.

Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.

Child F, Ortiz-Romero PL, Alvarez R, Bagot M, Stadler R, Weichenthal M, Alves R, Quaglino P, Beylot-Barry M, Cowan R, Geskin LJ, Pérez-Ferriols A, Hellemans P, Elsayed Y, Phelps C, Forslund A, Kamida M, Zinzani PL.

Br J Dermatol. 2016 Jul;175(1):80-8. doi: 10.1111/bjd.14427. Epub 2016 Jun 2.

PMID:
26836950
9.

Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.

Balakrishnan K, Ravandi F, Bantia S, Franklin A, Gandhi V.

Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):458-66. doi: 10.1016/j.clml.2013.04.009. Epub 2013 Jun 15.

10.
11.

Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.

Duvic M.

Oncology (Williston Park). 2007 Feb;21(2 Suppl 1):33-40. Review.

12.

Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.

Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N.

Clin Lymphoma Myeloma. 2006 Jul;7(1):51-8.

PMID:
16879770
13.

Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.

Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, Gerami P, Kuzel TM.

Leuk Lymphoma. 2009 Dec;50(12):1969-76. doi: 10.3109/10428190903216770.

PMID:
19860617
14.

Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients.

Anadolu RY, Birol A, Sanli H, Erdem C, Türsen U.

Int J Dermatol. 2005 Jul;44(7):559-65.

PMID:
15985024
15.

A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).

Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, Bantia S, Davisson J, Wierda WG, Faderl S, Kantarjian H, Thomas D.

Blood. 2005 Dec 15;106(13):4253-60. Epub 2005 Aug 30.

16.

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.

Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F.

Blood. 2010 Aug 12;116(6):886-92. doi: 10.1182/blood-2010-02-272039. Epub 2010 Apr 28.

17.

Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.

Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V.

Blood. 2006 Oct 1;108(7):2392-8. Epub 2006 Jun 15.

18.

Acitretin for the treatment of cutaneous T-cell lymphoma.

Cheeley J, Sahn RE, DeLong LK, Parker SR.

J Am Acad Dermatol. 2013 Feb;68(2):247-54. doi: 10.1016/j.jaad.2012.07.013. Epub 2012 Aug 20.

PMID:
22917895
19.
20.

Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.

Jumbou O, N'Guyen JM, Tessier MH, Legoux B, Dréno B.

Br J Dermatol. 1999 Mar;140(3):427-31.

PMID:
10233261

Supplemental Content

Support Center